NCT06881823 2025-12-29
NeoPSMA
Novartis
Phase 1/2 Withdrawn
Clinical Trials
26 trialsNCT06795178 2025-04-27
KATANA E3M
Foresee Pharmaceuticals Co., Ltd.
Phase 3 Withdrawn
NCT06795191 2025-04-27
KATANA E6M
Foresee Pharmaceuticals Co., Ltd.
Phase 3 Withdrawn
NCT06457854 2025-03-12
PROCeed-BR
AstraZeneca
Withdrawn
NCT02608359 2025-02-03
A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer
Johnson & Johnson Private Limited
Withdrawn
NCT02905201 2025-02-03
TOGETHER
Janssen Research & Development, LLC
Withdrawn
NCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
NCT03990194 2024-10-31
LEPTO
RECORDATI GROUP
Withdrawn
NCT03494803 2023-12-22
Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC
HKGepitherapeutics
Withdrawn
NCT05454371 2023-11-13
URODETECT-WP2
Novosanis NV
Phase NA Withdrawn
NCT01792882 2023-02-28
GBCPRT0008
Global BioClinical
Withdrawn
NCT05191017 2022-08-05
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
Nuvation Bio Inc.
Phase 1/2 Withdrawn
NCT03495479 2021-10-18
CAMPAS
Omnitura Therapeutics, Inc.
Withdrawn
NCT01566045 2021-04-28
MRI/TRUS Fusion Guided Prostate Biopsy- An Improved Way to Detect and Quantify Prostate Cancer
Philips Healthcare
Phase NA Withdrawn
NCT03589781 2021-03-30
Investigating the Effects of Mikei® Red Reishi Essence EX on the Immune System of Prostate Cancer Patients and Patients With Non-cancerous Conditions of the Prostate
Nikkei (Canada) Marketing Limited
Phase NA Withdrawn
NCT03325127 2018-10-31
Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study
Bayer
Withdrawn
NCT01188408 2018-03-12
Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer
INSYS Therapeutics Inc
Phase 2 Withdrawn
NCT00691899 2016-08-12
A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)
Merck Sharp & Dohme LLC
Phase 3 Withdrawn
NCT01173146 2016-05-25
Imaging of Residual Tumor During Prostatectomy
Spectros Corporation
Withdrawn
NCT01692483 2015-12-02
Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer
Janssen Pharmaceutica
Withdrawn
NCT01279785 2015-11-25
A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy
Molecular Insight Pharmaceuticals, Inc.
Withdrawn
NCT02424513 2015-06-02
A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer
ImaginAb, Inc.
Phase 2 Withdrawn
NCT01214291 2013-11-15
TREAT2
GTx
Phase 3 Withdrawn
NCT01197209 2013-08-23
Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer
Momotaro-Gene Inc.
Phase 1 Withdrawn
NCT00043212 2013-05-01
Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.
Northwest Biotherapeutics
Phase 3 Withdrawn
NCT00728533 2011-03-18
Open-Label, Randomised Parallel-Group Study
Ferring Pharmaceuticals
Phase 3 Withdrawn